Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Blood

• Publication date

  2004-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2002-11-3615PMID 12947008
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).

  2003cited by this paper
• Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers

  2003cited by this paper
• Review of “Minitransplantation”: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

  2003cited by this paper
• Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

  2002cited by this paper
• Sexuality and Sexual Dysfunction in Gynecological Psychooncology

  2002cited by this paper
• Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.

  2002cited by this paper
• Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning

  2002cited by this paper
• Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

  2002cited by this paper
• Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease.

  2002cited by this paper
• Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

  2001cited by this paper
• Progress in CLL, chemotherapy, antibodies and transplantation.

  2001influential reference
• Dose‐reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis

  2001cited by this paper
• Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.

  2001cited by this paper
• Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.

  2001cited by this paper
• A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome

  2001influential reference
• Acute left ventricular failure following melphalan and fludarabine conditioning

  2001cited by this paper
• Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients.

  2000cited by this paper
• In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

  2000cited by this paper
• Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation

  2000cited by this paper
• Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma

  2000cited by this paper
• 5-Fluorouracil: Synchronous Application of Continuous and Bolus Therapy in Heavily Pretreated Metastatic Colorectal Cancer: A Phase I/II Study

  2000cited by this paper
• Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: Non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect

  2000cited by this paper
• Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.

  2000cited by this paper
• Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or Cytosine arabinoside

  1999cited by this paper
• DNA alkylation and interstrand cross-linking by treosulfan

  1999cited by this paper
• Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo.

  1999cited by this paper
• Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group.

  1999cited by this paper
• Treosulfan as an alternative conditioning agent in bone marrow transplantation.

  1999cited by this paper
• Increased Risk of Chronic Graft-Versus-Host Disease, Obstructive Bronchiolitis, and Alopecia With Busulfan Versus Total Body Irradiation: Long-Term Results of a Randomized Trial in Allogeneic Marrow Recipients With Leukemia

  1999cited by this paper
• Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

  1998cited by this paper
• Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

  1998cited by this paper
• Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2.

  1998cited by this paper
• Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors

  1998cited by this paper
• Treosulfan as an effective second-line therapy in ovarian cancer.

  1998cited by this paper
• The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro.

  1998cited by this paper
• DNA alkylation and interstrand crosslinking by treosulfan

  1997cited by this paper
• Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.

  1997influential reference
• Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

  1997cited by this paper
• A Phase I Dose Escalation Trial of Intravenous Treosulfan in Refractory Cancer

  1996cited by this paper
• Fludarabine phosphate in the treatment of chronic lymphocytic leukemia.

  1990cited by this paper
• Single-agent oral etoposide for elderly small cell lung cancer patients.

  1990cited by this paper
• Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma

  1990cited by this paper
• Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate.

  1970cited by this paper

• First Reported Case of Treosulfan-Induced Fixed Drug Eruption.

  2026cites this paper
• HSCT Conditioning for Children: The Art in the Science

  2026cites this paper
• Risk stratification and impact of donor type on breakthrough invasive fungal infections in haematopoietic cell transplant with post-transplant cyclophosphamide and mould-active prophylaxis

  2025cites this paper
• New age HCT conditioning regimens: what works and why?

  2025cites this paper
• The effect of threosulfan-based versus busulfan-based preparation regimens on transplant outcomes.

  2025cites this paper
• Current status of conditioning regimens in haploidentical hematopoietic cell transplantation

  2024cites this paper
• Outpatient management of patients conditioned with Fludarabine and Treosulfan prior to allogeneic hematopoietic cell transplantation.

  2024cites this paper
• Sequential conditioning with FLAMSA does not improve outcomes of allogeneic stem cell transplantation in CMML patients.

  2024cites this paper
• Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells

  2024cites this paper
• Outcomes from hematopoietic stem cell transplantation following treosulfan‐based conditioning: A clinical and pharmacokinetic analysis

  2024cites this paper
• Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center

  2024cites this paper
• Surface engineering of lipid nanoparticles: targeted nucleic acid delivery and beyond

  2023cites this paper
• Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT

  2023cites this paper
• Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis

  2022influential citation
• Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation

  2022cites this paper
• Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial

  2022cites this paper
• Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

  2022cites this paper
• Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

  2022cites this paper
• Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma

  2022cites this paper
• Evaluation of treosulfan cumulative exposure in paediatric patients through population pharmacokinetics and dosing simulations

  2022cites this paper
• Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms

  2021cites this paper
• Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial

  2021cites this paper
• Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation

  2021cites this paper
• Comparison of efficacy and toxicity of treosulfan-fludarabine and busulfan-cyclophosphamide conditioning regimens in patients undergoing allogeneic stem cell transplantation

  2021cites this paper
• Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant Transplantation and Cellular Therapy

  2021cites this paper
• Myelodysplastic syndromes: moving towards personalized management

  2020cites this paper
• Treosulfan – fl udarabine – thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies

  2020cites this paper
• Long-Term Outcomes of Treosulfan- vs. Busulfan-Based Conditioning Regimen for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia Before Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis

  2020cites this paper
• Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study.

  2020cites this paper
• Treosulfan-Based Conditioning Regimen in Haematopoietic Stem Cell Transplantation with TCRαβ/CD19 Depletion in Nijmegen Breakage Syndrome.

  2020cites this paper
• Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies

  2020cites this paper
• Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.

  2020cites this paper
• Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

  2019cites this paper
• Kinetics of in Vitro Guanine- N7-Alkylation in Calf Thymus DNA by (2 S,3 S)-1,2-Epoxybutane-3,4-diol 4-methanesulfonate and (2 S,3 S)-1,2:3,4-Diepoxybutane: Revision of the Mechanism of DNA Cross-Linking by the Prodrug Treosulfan.

  2019cites this paper
• Conditioning Perspectives for Primary Immunodeficiency Stem Cell Transplants

  2019cites this paper
• Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide

  2019cites this paper
• Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation

  2019cites this paper
• Outcome of treosulfan‐based reduced‐toxicity conditioning regimens for HSCT in high‐risk patients with primary immune deficiencies

  2018cites this paper
• Preparative Regimen for Hematopoietic Stem Cell Transplantation (HSCT) in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia

  2017cites this paper
• Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study.

  2017cites this paper
• Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.

  2017cites this paper
• Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML

  2017cites this paper
• Long‐term outcome after a treosulfan‐based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  2017influential citation
• Intersecting Worlds of Transfusion and Transplantation Medicine: An International Symposium Organized by the Canadian Blood Services Centre for Innovation.

  2017cites this paper
• Treosulfan–fludarabine–thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho‐proliferative disease. A single centre study

  2016cites this paper
• Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases

  2015cites this paper
• Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1/2–NF-κB and JNK–AP-1 signaling pathways

  2015cites this paper
• Bone Marrow–Derived Stem Cells and Strategies for Treatment of Nervous System Disorders

  2015cites this paper
• Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)

  2015cites this paper
• Treosulfan‐based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease

  2015cites this paper
• Treatment of High-Risk T-NHL with Stem Cell Transplantation: A Single Center Experience

  2015cites this paper
• TRASPLANTE DE PROGENITORES HEMATOPOYÉTICOS EN ENFERMEDADES GENÉTICAS CON RÉGIMEN DE ACONDICIONAMIENTO DE INTENSIDAD REDUCIDA EN PACIENTES PEDIÁTRICOS

  2015cites this paper
• Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.

  2014cites this paper
• Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.

  2014cites this paper
• Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning

  2014cites this paper
• Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma.

  2014cites this paper
• Allogeneic stem cell transplantation in patients above 55: suggestion for a further stratification of the HCT-CI

  2014cites this paper
• Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.

  2013cites this paper
• Treosulfan: reduced toxicity conditioning for allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome

  2013cites this paper
• Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation—a matched pair analysis

  2013cites this paper
• Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience

  2013cites this paper
• Escalating Topotecan in Combination with Treosulfan has Acceptable Toxicity in Advanced Pediatric Sarcomas

  2013cites this paper
• hematopoietic stem cell transplantation in acute myeloid leukemia Conditioning with 8 Gy total body irradiation and fludarabine for allogeneic

  2013cites this paper
• Prevention and diagnostics of invasive fungal infections in acute leukaemia and allogeneic stem cell transplantation

  2012cites this paper
• Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor

  2012cites this paper
• HPLC method for determination of biologically active epoxy-transformers of treosulfan in human plasma: pharmacokinetic application.

  2012cites this paper
• Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike

  2012cites this paper
• Monoamine ox idase inhib itors and the occurrence of intraoperat ive haemodynamic events

  2012cites this paper
• Direct high-performance liquid chromatography method with refractometric detection designed for stability studies of treosulfan and its biologically active epoxy-transformers.

  2012cites this paper
• Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

  2012cites this paper
• Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation.

  2012cites this paper
• Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine

  2012cites this paper
• Toxoplasmosis after allogeneic stem cell transplantation—a single centre experience

  2012cites this paper
• Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies

  2012cites this paper
• Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.

  2012cites this paper
• Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning

  2012cites this paper
• Kingdom experience transplantation in children with primary immunodeficiency: United Treosulfan-based conditioning regimens for hematopoietic stem cell

  2012cites this paper
• Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

  2011cites this paper
• Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia

  2011influential citation
• Umbilical Cord Blood Hematopoietic Stem Cell Transplantation, an Alternative to Bone Marrow

  2011cites this paper
• Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors.

  2011cites this paper
• Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party

  2011cites this paper
• Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome

  2011cites this paper
• results of the German CLL Study Group CLL3X trial poor-risk chronic lymphocytic leukemia: long-term clinical and MRD Allogeneic stem cell transplantation provides durable disease control in

  2011cites this paper
• Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.

  2011cites this paper
• Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial

  2011cites this paper
• Mucositis after Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation

  2011cites this paper
• Przeszczepianie komórek krwiotwórczych ze zredukowaną toksycznością i intensywnością kondycjonowania u dzieci: rola treosulfanu ☆

  2011cites this paper
• Advanced-Stage III/IV Follicular Lymphoma

  2010cites this paper
• Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.

  2010cites this paper
• Bone marrow transplantation for primary immunodeficiency diseases.

  2010cites this paper
• Invasive Aspergillus infections in allo-SCT recipients: environmental sampling, nasal and oral colonization and galactomannan testing

  2010cites this paper
• Late extramedullary relapse after allogeneic transplantation in a case of variant hairy cell leukaemia

  2010cites this paper
• The role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation

  2010cites this paper
• Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia : long-term clinical and MRD results of the German CLL Study Group CLL 3 X trial

  2010cites this paper
• Challenges in Treating Older Patients with Acute Myeloid Leukemia

  2010cites this paper
• MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease

  2010cites this paper
• Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.

  2010cites this paper
• High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation

  2010influential citation
• Reduced intensity transplantation for primary immunodeficiency disorders.

  2010cites this paper